Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer

Tomoko Jogo; Yoshiaki Nakamura; Kohei Shitara; Hideaki Bando; Hisateru Yasui; Taito Esaki; Tetsuji Terazawa; Taroh Satoh; Eiji Shinozaki; Tomohiro Nishina; Yu Sunakawa; Yoshito Komatsu; Hiroki Hara; Eiji Oki; Nobuhisa Matsuhashi; Takashi Ohta; Takeshi Kato; Koushiro Ohtsubo; Takeshi Kawakami; Naohiro Okano; Yoshiyuki Yamamoto; Takanobu Yamada; Akihito Tsuji; Justin I. Odegaard; Hiroya Taniguchi; Toshihiko Doi; Satoshi Fujii; Takayuki Yoshino

doi:10.1158/1078-0432.ccr-21-1414

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

PURPOSE: amplification and co-occurring resistance mechanisms in advanced gastric cancer. EXPERIMENTAL DESIGN: -amplified advanced gastric cancer identified by ctDNA sequencing who received FGFR inhibitors. RESULTS: copy number. CONCLUSIONS: -amplified advanced gastric cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jogo et al. (2021) studied this question.

synapsesocial.com/papers/6a03ca33e5221f96ef1dcf09 https://doi.org/10.1158/1078-0432.ccr-21-1414

View Full Paper

Ask AI

Bookmark

Share

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading